Premium
Relationship between cancer and oral pemphigoid patients with antibodies to α6‐integrin
Author(s) -
Malik Mohsin,
Gürcan Hakan M.,
Christen William,
Razzaque Ahmed A.
Publication year - 2007
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1111/j.1600-0714.2006.00483.x
Subject(s) - medicine , malignancy , mucocutaneous zone , cancer , autoantibody , incidence (geometry) , pemphigoid , epidemiology , antibody , bullous pemphigoid , cancer registry , relative risk , gastroenterology , dermatology , oncology , disease , immunology , confidence interval , physics , optics
Background: Mucous membrane pemphigoid is an autoimmune mucocutaneous blistering disease. A subset, known as anti‐epiligrin cicatricial pemphigoid is associated with a high risk for malignancy. Oral pemphigoid (OP) is limited to the oral cavity. The purpose of this study was to determine the association between malignancy and patients with OP with antibodies to α 6‐integrin subunit. Methods: We determined the incidence of cancer in 72 patients with OP and compared it to the expected incidence using age and sex‐specific rates of malignancy in the National Cancer Institute's Surveillance, Epidemiology, and End Results (NCI SEER) Registry. Results: During a mean observation period of 9.1 years (range: 2.8–40), for 70, three OP patients developed malignancies. The expected number of cancers based on the NCI SEER Registry was 8.83. The relative risk for cancer in OP patients, with autoantibodies to α 6‐integrin, was 0.34 (95% CI, 0.07–0.99, P < 0.05). Conclusion: It appears that patients with OP, with antibodies to α 6, may have a possible reduced relative risk for developing cancer.